Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond Rule of Five and PROTACs in Modern Drug Discovery: Polarity Reducers, Chameleonicity, and the Evolving Physicochemical Landscape
Edward Price, Manuel Weinheimer, Alexey Rivkin, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5683-5698
Closed Access | Times Cited: 25

Showing 25 citing articles:

Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment
Ojochenemi A. Enejoh, Chinelo H. Okonkwo, Hector Nortey, et al.
Frontiers in Chemistry (2025) Vol. 12
Open Access | Times Cited: 1
Macrocyclization as a Strategy for Kinetic Solubility Improvement: A Comparative Analysis of Matched Molecular Pairs
Carlo Walz, Moritz Spiske, Magnus W. Walter, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Use of Aldehyde–Alkyne–Amine Couplings to Generate Medicinal Chemistry-Relevant Linkers
Andrew McGown, Vesna Vetma, Damien Crépin, et al.
ACS Medicinal Chemistry Letters (2025)
Open Access
Novel dual-targeting PROTAC degraders of GSK-3β and CDK5: A promising approach for pancreatic cancer treatment
Neerasa Jayaprakash, Byeonggwan Kim, Hye Jin Chung
Bioorganic & Medicinal Chemistry (2025) Vol. 120, pp. 118085-118085
Closed Access
Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer
Yubo Wang, Mengmeng Wang, Ma Lan, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders
Giulia Apprato, Giulia Caron, Gauri Deshmukh, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access
Grand challenges in oral drug delivery
Driton Vllasaliu
Frontiers in Drug Delivery (2025) Vol. 5
Open Access
Pharmacomodulation of the Redox-Active Lead Plasmodione: Synthesis of Substituted 2-Benzylnaphthoquinone Derivatives, Antiplasmodial Activities, and Physicochemical Properties
Armin Presser, Gregor Blaser, Eva‐Maria Pferschy‐Wenzig, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2114-2114
Open Access
Linker-Determined Folding and Hydrophobic Interactions Explain a Major Difference in PROTAC Cell Permeability
Vasanthanathan Poongavanam, Stefan Peintner, Yordanos Esubalew Abeje, et al.
ACS Medicinal Chemistry Letters (2025)
Open Access
Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers
Aishwarya Saraswat, Hari Priya Vemana, Vikas V. Dukhande, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 3, pp. 102292-102292
Open Access | Times Cited: 4
Computational approaches to aid PROTAC drug discovery
Sohini Chakraborti, Kirsten McAulay
Elsevier eBooks (2025)
Closed Access
High-Throughput SFC-MS/MS Method to Measure EPSA and Predict Human Permeability
Yue-Ting Wang, Edward Price, Mei Feng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13765-13777
Closed Access | Times Cited: 3
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
Molecular properties, including chameleonicity, as essential tools for designing the next generation of oral beyond rule of five drugs
Giulia Caron, Diego García Jiménez, Maura Vallaro, et al.
ADMET & DMPK (2024)
Open Access | Times Cited: 3
Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation
Shareef Shaik, Prasanna Kumar Reddy Gayam, Manish Chaudhary, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107868-107868
Open Access | Times Cited: 3
Next steps for targeted protein degradation
Mackenzie W. Krone, Craig M. Crews
Cell chemical biology (2024)
Closed Access | Times Cited: 3
Druggability of Pharmaceutical Compounds Using Lipinski Rules with Machine Learning
Samukelisiwe Nhlapho, Musawenkosi L. Nyathi, Brendeline Ngwenya, et al.
Sciences of Pharmacy (2024) Vol. 3, Iss. 4, pp. 177-192
Open Access | Times Cited: 3
Conquering the beyond Rule of Five Space with an Optimized High-Throughput Caco-2 Assay to Close Gaps in Absorption Prediction
Patricia Muschong, Khader Awwad, Edward Price, et al.
Pharmaceutics (2024) Vol. 16, Iss. 7, pp. 846-846
Open Access | Times Cited: 2
Property-based optimisation of PROTACs
James S. Scott, Iacovos N. Michaelides, Markus Schade
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
Diana Castagna, Benoit Gourdet, Roland Hjerpe, et al.
Progress in medicinal chemistry (2024), pp. 61-160
Closed Access | Times Cited: 1
Closing the Design–Make–Test–Analyze Loop: Interplay between Experiments and Predictions Drives PROTACs Bioavailability
Zulma Santisteban Valencia, Jennifer Kingston, Filip Miljković, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 20242-20257
Closed Access | Times Cited: 1
Synthesis and Cytotoxic Activity of Madecassic Acid-Silybin Conjugate Compounds in Liver Cancer Cells
Chien Van Tran, Tran Thi Phuong Thao, Anh The Nguyen, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 10, pp. 3418-3432
Open Access
Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474
Scott D. Edmondson
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18017-18021
Closed Access
Temporal and Spatial Characterization of CUL3KLHL20-driven Targeted Degradation of BET family, BRD Proteins by the Macrocycle-based Degrader BTR2004
Phoebe H. Fechtmeyer, Johannes T.‐H. Yeh
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
AURA: Accelerating Drug Discovery with Accuracy, Utility, and Rank-Order Assessment for Data-Driven Decision Making
Edward Price, Virginia Saulnier, Cory Kalvass, et al.
Journal of Pharmaceutical Sciences (2024)
Open Access
Page 1

Scroll to top